Clinical trial NCT05191914: Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 Inhibitors
Official title: Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to Cyclin-dependent Kinases（CDK）4/6 Inhibitors
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Breast Cancer
Lead sponsor: Liaoning Cancer Hospital & Institute
Sponsor class: OTHER
First posted: 2022-01-14
Enrollment: 20
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The trial used a multicenter, open, single-arm design in which patients were treated with Chidamide combined with Fulvestrant.The primary objective is to evaluate the preliminary efficacy and safety of Chidamide in combination with Fulvestrant.Patients included in the trial were advanced breast cancer progressing on first-line aromatase inhibitor + Cyclin-dependent kinases（CDK）4/6i rescue therapy.


Eligibility criteria: Inclusion Criteria:

* age ≥ 18 years, postmenopausal \* female patients;
* histologically or cytologically confirmed hormone receptor positive (ER positive, PR positive or negative), human epidermal growth factor receptor 2 negative # breast cancer patients;
* the disease before enrollment is overall unresectable locally advanced or metastatic breast cancer, and at least one measurable lesion or no measurable lesion and bone metastasis alone patients;
* for locally advanced or metastatic breast cancer, previous progression by first-line aromatase inhibitors combined with Cyclin-dependent kinases（CDK）4/6 inhibitors;
* the total number of regimens regardless of rescue therapy or adjuvant therapy before enrollment is ≤ 3, of which the number of rescue chemotherapy regimens is ≤ 1;
* Eastern Collaborative Oncology Group（ECOG） score 0-1;
* absolute neutrophil count ≥ 1.5 × 109/L, platelets ≥ 100 × 109/L, hemoglobin ≥ 90 g/L;
* expected survival time ≥ 3 months;
* Voluntarily participate in this clinical trial and sign the written informed consent form

Exclusion Criteria:

* no measurable lesions (except simple bone metastasis), such as pleural or pericardial exudate, ascites, etc.;
* underwent major surgical procedures or significant trauma before enrollment, or patients are expected to undergo major surgical treatment;
* Patients who have previously been treated with fulvestrant or histone deacetylase inhibitors (including romidepsin, vorinostat), but have received only one cycle (≤ 2 times, d1, d15, respectively) of fulvestrant within 28 days (before enrollment) are allowed;
* known to have a history of allergy to the drug components of this protocol;
* the presence of brain (membrane) metastasis during the screening period;
* a history of immunodeficiency, including HIV test positive, or suffering from other acquired, congenital immunodeficiency diseases, or a history of organ transplantation;
* uncontrolled important cardiovascular disease;
* abnormal liver function \[total bilirubin \> 1.5 times the upper limit of normal; alanine aminotrans（ALT）/aspartate aminotransferase（AST） \> 2.5 times the upper limit of normal in patients without liver metastasis, alanine aminotrans（ALT）/aspartate aminotransferase（AST） \> 5 times the upper limit of normal in patients with liver metastasis\], abnormal renal function (serum creatinine \> 1.5 times the upper limit of normal);
* pregnant, lactating female patients or women of childbearing potential baseline pregnancy test positive; or during the study and the last dose of at least 8 to take effective contraceptive measures in subjects of childbearing age;
* According to the investigator's judgment, there are concomitant diseases that seriously endanger the patient's safety or affect the patient's completion of the study (such as: severe hypertension, diabetes, thyroid disease, active infection, etc.);
* History of definite neurological or psychiatric disorders, including epilepsy or dementia;
* Unsuitable for participation in the study as judged by the investigator.

Primary outcomes:
measure: Progression Free Survival (PFS)
timeFrame: Up to approximately 16 months
Secondary outcomes:
measure: Overall Response Rate (ORR)
timeFrame: Up to approximately 16 months
measure: Overall Survival (OS)
timeFrame: Up to approximately 38 months
measure: Clinical Benefit Rate (CBR)
timeFrame: Up to approximately 16 months
measure: Duration of Response (DOR)
timeFrame: Up to approximately 16 months
Other outcomes:
Locations:
Study officials:
References: